ERBB2-Mutated Metastatic Lung Adenocarcinoma With Limited Disease Control Across Multiple Therapies
This lung cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- ERBB2 V776delinsVC mutation
- Sex
- female
- Treatment
- chemotherapy and targeted therapy
- Outcome
- Setback / Progression
Treatment course, step by step
- Cisplatin and pemetrexed were started, with initial progression.
- Bevacizumab was then added to cisplatin and pemetrexed, producing stable disease during a total 4.5-month treatment period.
- Trastuzumab plus paclitaxel followed for 2 months before progression.
- Erlotinib was then given for 1 month before further progression.
What happened, in summary
A woman who had never smoked had metastatic lung adenocarcinoma with an ERBB2 V776delinsVC mutation. She started cisplatin and pemetrexed, but the cancer initially progressed. Bevacizumab was then added to the chemotherapy regimen, after which stable disease was documented during a total treatment period of 4.5 months. She next received trastuzumab plus paclitaxel for 2 months, but the disease progressed. Erlotinib followed for 1 month and was also associated with further progression. Her course showed a short period of disease control after bevacizumab was added, followed by progression through later HER2-directed and systemic treatments.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Bevacizumab for Lung Cancer 37 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer